Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this phase 1B study, patients with ER-positive/HER2-negative metastatic breast cancer receiving combined pegylated liposomal doxorubicin and pembrolizumab had a disease control rate of 67% with responses lasting a median of 11 months; the treatment was well tolerated and showed potential for extended use.

High MUC-18/MCAM levels in blood indicate a worse outlook for melanoma patients.

This study reports that a clinical prognostic model based on immune-related genes improved survival prediction for patients with clear cell renal cell carcinoma, also identifying potential drugs targeting the gene DOCK8.

This study reports that CD200R expression is significantly reduced in an experimental mouse model of scarring alopecia, suggesting a potential role for this pathway in immune regulation and hair follicle protection.

This meta-analysis suggests that combining Kang-ai injection with platinum-based chemotherapy may improve tumor response, performance status, immune functions, and reduce adverse reactions in patients with advanced non-small cell lung cancer.

In this study, Mononuclear Cells provided site-specific protection against chemotherapy-induced alopecia in rats treated with Ara-C, but not with CTX or VP-16, while PRP showed no protective effect.

This study found that the MD-3 antibody significantly improved the survival of hair follicle allografts in nonhuman primates by reducing T-cell infiltration.

This study reported that VCP combination chemotherapy achieved a complete response in 53% of advanced non-Hodgkin's lymphoma patients, although more intensive treatment may be needed for improved outcomes.

This study analyzed blood samples from individuals with alopecia areata and found that NKG2D+ immune cells, particularly memory-like NK cells, may better correlate with disease activity compared to CD8+ cells, though significant variability among individuals complicates these findings.

This study found that CD34- melanocyte stem cells regenerated pigmentation more efficiently, while CD34+ cells showed potential for neuron myelination, suggesting different therapeutic applications for each population.

This review discusses the bidirectional interactions between human mast cells and CD8 T cells in the skin, particularly in the context of disorders like psoriasis, atopic dermatitis, and vitiligo, and reports no new findings.

In this study, researchers report that CDK inhibitors like palbociclib and ribociclib, initially developed for cancer therapy, show potential in treating neutrophilic inflammation-related conditions such as ARDS and psoriasis, although their clinical repurposing requires further research on safety and dose adjustments.

The study found that the combined administration of regulatory T cells and rapamycin improved outcomes in an experimental model of chronic graft-versus-host disease.

This study investigated human hair follicle bulge cells and found that those with reduced CD200 expression exhibited enhanced hair regenerative capability, refining the functional understanding of bulge cell heterogeneity and providing insights for optimizing bulge cell–based hair regeneration techniques.

This study identified CD28, GZMB, and CD1C as key immune regulators in alopecia areata, highlighting CD28 as a potential therapeutic target with a promising safety profile, using a proteome-anchored multi-omics approach to uncover actionable targets for this autoimmune hair-loss disorder.

This study found that the DOX derivative AD198 more effectively inhibited cell viability and induced apoptosis in canine cancer cell lines K9TCC and K9OSA compared to DOX in vitro.

This study found that the novel anti-HER2 antibody RC48 demonstrated promising activity and manageable safety in patients with HER2-overexpressing, advanced gastric or gastroesophageal junction cancer after at least two prior chemotherapy lines.

sCD83 shows promise for treating hair loss by promoting growth and reducing inflammation.

This study found that B cells have dual roles in tumor immunity, with regulatory B cells potentially hindering immune responses against tumors in the melanoma mouse model.

In this study, among Indian patients with triple-negative breast cancer, Ki-67 expression levels were high but not significantly associated with treatment response to a neoadjuvant docetaxel-carboplatin regimen, which showed complete clinical, imaging, and pathological response rates of 39.13%, 34.78%, and 47.61%, respectively.

PCFCL may have unrecognized subtypes and needs more research.

This study found that Baricitinib significantly reduced hair loss and immune response in a mouse model of alopecia areata.

This study found that soluble CD83 (sCD83) accelerated chronic and hard-to-heal wound healing and improved inflammatory and pro-resolving cytokine profiles, suggesting potential for therapeutic use.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

TAK-279 effectively reduces psoriasis symptoms and is safe.

This review examines various immunomodulatory therapies for cutaneous lymphoma and notes that they are most effective in the disease's early stages.

This study reports that cannabinoid receptor type 1 may influence psoriasis development by modulating laminin-511 expression, suggesting a potential target for treatment.

Results are not reported in this abstract, which notes that while Janus kinase inhibitors like baricitinib show therapeutic benefits for alopecia areata, the mechanisms and reliable predictors of response remain unclear.

This study found that DEB-BACE combined with systemic chemotherapy was more effective than chemotherapy alone for unresectable lung squamous cell carcinoma, reducing side effects and improving survival rates.